14:18:32 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-07 Bokslutskommuniké 2024
2024-10-25 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-05-22 Extra Bolagsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-04-10 X-dag ordinarie utdelning EPIS B 0.00 SEK
2024-04-09 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-03 X-dag ordinarie utdelning EPIS B 0.00 SEK
2023-05-02 Årsstämma 2023
2023-04-28 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-04-29 Kvartalsrapport 2022-Q1
2022-04-05 X-dag ordinarie utdelning EPIS B 0.00 SEK
2022-04-04 Årsstämma 2022
2022-02-11 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-05-11 X-dag ordinarie utdelning EPIS B 0.00 SEK
2021-05-10 Årsstämma 2021
2021-04-29 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-04-24 Kvartalsrapport 2020-Q1
2020-04-03 X-dag ordinarie utdelning EPIS B 0.00 SEK
2020-04-02 Årsstämma 2020
2020-03-10 Extra Bolagsstämma 2020
2020-02-07 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-07-19 Kvartalsrapport 2019-Q2
2019-05-07 Extra Bolagsstämma 2019
2019-04-26 Kvartalsrapport 2019-Q1
2019-04-09 X-dag ordinarie utdelning EPIS B 0.00 SEK
2019-04-08 Årsstämma 2019
2019-02-08 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-20 Kvartalsrapport 2018-Q2
2018-04-27 Kvartalsrapport 2018-Q1
2018-04-10 X-dag ordinarie utdelning EPIS B 0.00 SEK
2018-04-09 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-23 X-dag ordinarie utdelning EPIS B 0.00 SEK
2017-05-22 Årsstämma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-02-24 Bokslutskommuniké 2016
2017-02-20 Extra Bolagsstämma 2017
2016-11-04 Kvartalsrapport 2016-Q3
2016-08-19 Kvartalsrapport 2016-Q2
2016-05-25 X-dag ordinarie utdelning EPIS B 0.00 SEK
2016-05-24 Årsstämma 2016
2016-05-17 Kvartalsrapport 2016-Q1
2016-02-23 Bokslutskommuniké 2015
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-05-07 X-dag ordinarie utdelning EPIS B 0.00 SEK
2015-05-06 Kvartalsrapport 2015-Q1
2015-05-06 Årsstämma 2015
2015-02-20 Bokslutskommuniké 2014
2014-11-07 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-04 X-dag ordinarie utdelning EPIS B 0.00 SEK
2014-06-03 Årsstämma 2014
2014-05-09 Kvartalsrapport 2014-Q1
2014-02-21 Bokslutskommuniké 2013
2014-02-12 Extra Bolagsstämma 2014
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-03 X-dag ordinarie utdelning EPIS B 0.00 SEK
2013-05-03 Kvartalsrapport 2013-Q1
2013-05-02 Årsstämma 2013
2013-04-03 Extra Bolagsstämma 2013
2013-02-21 Bokslutskommuniké 2012
2012-11-21 Kvartalsrapport 2012-Q3
2012-08-22 Kvartalsrapport 2012-Q2
2012-06-04 Årsstämma 2012
2012-05-04 Kvartalsrapport 2012-Q1
2012-02-21 Bokslutskommuniké 2011
2011-11-21 Kvartalsrapport 2011-Q3
2011-08-22 Kvartalsrapport 2011-Q2
2011-07-20 Split EPIS B 6:1
2011-06-30 Årsstämma 2011
2011-05-21 Kvartalsrapport 2011-Q1
2011-05-13 Extra Bolagsstämma 2011
2011-05-02 Kvartalsrapport 2011-Q1
2011-02-18 Bokslutskommuniké 2010
2010-08-30 Extra Bolagsstämma 2010

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Episurf Medical är ett verksamt inom medicinteknik. Bolaget driver forskning och utveckling av produkter som används för behandling av broskskador. Episurfs primära fokus är riktat mot återhämtning av knäleder men bolagets implantat kan även appliceras på övriga leder. Episurf Medical befinner sig i preklinisk verifieringsfas och har sitt huvudkontor i Stockholm.
2024-05-24 11:30:00

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

On 22 April 2024, Episurf Medical AB (publ) ("Episurf", "Episurf Medical" or the "Company"), (NASDAQ Stockholm: EPIS B) announced that the Board of Directors had, subject to the subsequent approval by an Extraordinary General Meeting (the "EGM"), resolved on a new issue of units with preferential rights for existing shareholders of up to approximately SEK 120 million before deduction of costs attributable to the rights issue (the "Rights Issue"). The Rights Issue is covered to approximately 75 percent, corresponding to approximately SEK 90 million, by subscription commitments and intentions as well as guarantee commitments. The Board of Directors' resolution on the Rights Issue was approved by the EGM held on 22 May 2024. A prospectus that has been prepared in connection with the Rights Issue has today, 24 May 2024, been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) ("SFSA") and is available in Swedish on Episurf's website https://episurf.com/, as well as on Pareto Securities' website www.paretosec.com.

Publication of the prospectus

Complete information about the Rights Issue is included in the prospectus that has been prepared by the Board of Directors of the Company and that today, 24 May 2024, has been approved and registered by the SFSA. The prospectus in Swedish is available on the Company's website (https://episurf.com/) and on Pareto Securities' website (www.paretosec.com). The prospectus will also be available in Swedish on SFSA's website (www.fi.se/sv/vara-register/prospektregistret/).

Application forms

The subscription period will commence on 28 May 2024. Subscription forms for subscription without preferential rights will be available on the Company's, Pareto Securities' and Nordic Issuing AB's respective websites. Subscription for units without preferential rights can also be made with Swedish BankID or Nordic eID via www.minasidor.nordic-issuing.se.

Timetable of the Rights Issue

24 May Record date for receipt of unit rights
2024
24 May Publication of the prospectus
2024
28 May - 7 Trading in unit rights
June 2024
28 May - Subscription period
12 June
2024
28 May - Trading in BTUs (paid subscribed units)
24 June
2024
13 June Expected announcement of the outcome of the
2024 Rights Issue
28 June Expected first day of trading in warrants of
2024 series TO13 B on Nasdaq First North Growth
Market
10 - 24 Exercise period for warrants of series TO13 B
February
2025

Advisors

Pareto Securities has been appointed as Sole Manager and Bookrunner in the Rights Issue. Hannes Snellman Advokatbyrå AB is legal adviser to Episurf in connection with the Rights Issue. Advokatfirman Vinge KB is legal adviser to the Sole Manager and Bookrunner in connection with the Rights Issue. Nordic Issuing acts as issuing agent in connection with the Rights Issue.